IXICO plc (GB:IXI) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
IXICO plc has secured a significant contract with a US-based client for providing imaging services in a Phase 2 clinical trial focused on Huntington’s Disease, valued at over £0.5 million over 2.5 years. This contract is part of IXICO’s strategy to expand its presence in the neuroscience imaging sector, leveraging its AI-driven platform to support research in neurodegenerative disorders. The deal underscores IXICO’s growth momentum and expertise in assisting clinical trials for conditions like Huntington’s, Parkinson’s, and Alzheimer’s diseases.
For further insights into GB:IXI stock, check out TipRanks’ Stock Analysis page.
